JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

JNJ

229.64

+0.81%↑

UNH

369.73

+0.08%↑

TMO

476.34

+1.91%↑

ISRG

454.78

+0.68%↑

ABT

90.61

-1.86%↓

Search

Cencora Inc

Open

BrancheGesundheitswesen

305.61 -2.05

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

298.7

Max

312.67

Schlüsselkennzahlen

By Trading Economics

Einkommen

906M

566M

Verkäufe

2.2B

86B

KGV

Branchendurchschnitt

37.19

67.147

EPS

4.08

Dividendenrendite

0.73

Gewinnspanne

0.659

Angestellte

47,000

EBITDA

858M

1B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+29.04% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.73%

2.36%

Nächstes Ergebnis

6. Mai 2026

Nächste Dividendenausschüttung

1. Juni 2026

Nächstes Ex-Dividendendatum

15. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-10B

60B

Vorheriger Eröffnungskurs

307.66

Vorheriger Schlusskurs

305.61

Nachrichtenstimmung

By Acuity

7%

93%

6 / 348 Ranking in Healthcare

Cencora Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2026, 23:53 UTC

Ergebnisse

Naver Posts Weaker First-Quarter Earnings

29. Apr. 2026, 23:41 UTC

Heiße Aktien

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. Apr. 2026, 23:55 UTC

Ergebnisse

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. Apr. 2026, 23:54 UTC

Ergebnisse

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. Apr. 2026, 23:52 UTC

Ergebnisse

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. Apr. 2026, 23:51 UTC

Ergebnisse

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. Apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan 1Q Net CNY1.70B, Down 14%

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan: Power Generation Down 2.9% as of End-March

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss Narrows>000002.SZ

29. Apr. 2026, 23:18 UTC

Ergebnisse

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. Apr. 2026, 23:17 UTC

Ergebnisse

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. Apr. 2026, 23:13 UTC

Ergebnisse

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. Apr. 2026, 23:12 UTC

Ergebnisse

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. Apr. 2026, 23:04 UTC

Ergebnisse

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. Apr. 2026, 23:04 UTC

Ergebnisse

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer-Vergleich

Kursveränderung

Cencora Inc Prognose

Kursziel

By TipRanks

29.04% Vorteil

12-Monats-Prognose

Durchschnitt 401.86 USD  29.04%

Hoch 429 USD

Tief 360 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cencora Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

6

Buy

2

Halten

0

Sell

Stimmung

By Acuity

6 / 348 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cencora Inc

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
help-icon Live chat